EydisBio Revenue and Competitors

EydisBio, Inc. is an early-stage biopharmaceutical company focused on developing potent and selective small molecule therapeutics targeting autoimmune and inflammatory disease with high unmet medical needs. EydisBio's TAK1 inhibitor program is primarily focused on targeting the over 40% of rheumatoid arthritis patients who either do not respond or lose response over time to approved anti-TNF biologics. Our highly potent and exquisitely selective, orally bioavailable TAK1 inhibitors are also being explored in additional autoimmune indications including the rare disease systemic sclerosis, viral-induced acute respiratory distress syndrome, and as an alternative to opioids in patients with chronic pain. We also have an oncology discovery program with promising early efficacy in treating patients with FLT3 mutation-positive AML and glioblastoma.